Hitachi Chemical Co. America, Ltd. (San Jose, California), a subsidiary of Hitachi Chemical (Tokyo) has completed its purchase of the 80.1% remaining membership interest in PCT Cell Therapy Services (PCT, New Jersey) from Caladrius Biosciences.
Following the acquisition, PCT has become an independent business unit dedicated to cell therapy and regenerative medicine within the life sciences division of Hitachi Chemical.
Hitachi Chemical will leverage PCT’s extensive experience in cell therapy development and manufacturing technology, wide-ranging manufacturing locations, sales network and other resources to expand and strengthen services in the United States and add services in Japan, Europe, and other regions. In addition, PCT will be able to expand manufacturing capacity, capabilities, and service offerings.
“The acquisition of PCT marks an important milestone in the expansion of Hitachi Chemical’s regenerative medicine-related businesses,” says Hisashi Maruyama, CEO, Hitachi Chemical.
By Kartik Kohli
Source: Chemical Week
ExxonMobil Corp. (Spring, Tex.) announced the startup of two new chemical production units at its Baytown, Texas, manufacturing facility. The $2 billion expansion is part of ExxonMobil’s long-term growth plans to deliver higher-value products from its U.S. Gulf Coast refining and chemical facilities.
Ineos Enterprises has announced the acquisition of Eramet Titanium & Iron (ETI) from Eramet for €230 million ($245 million). The deal was completed on Sept. 21 and takes immediate effect, following the satisfaction of regulatory approvals.
Arxada has appointed Sanjeev Rastogi as Chief Executive Officer (CEO), effective immediately. He succeeds Marc Doyle who led Arxada since its foundation and will join the company’s board of directors as a non-executive member.
